Stoke Therapeutics Inc. is set to report fourth-quarter results Monday, offering investors a window into the financial health of a biotech company whose shares have surged more than 500% from their 52-week low amid growing optimism about its experimental treatment for Dravet syndrome.
Analysts expect the company to post a loss of $0.73 per share on revenue of $5.4 million for the quarter ended December 2025, according to consensus estimates. That would represent a sequential decline from the prior quarter, when Stoke reported a loss of $0.65 per share on revenue of $10.6 million, though the company beat revenue expectations by 75% in that period.
Revenue estimates have risen 27.87% over the past two months, while EPS estimates have remained largely unchanged over the past week. The upward revision to revenue expectations comes as the company advances its lead asset, zorevunersen, through late-stage clinical development.
All 12 analysts covering the stock rate it a Strong Buy, with a mean price target of $45.10 -- implying 36% upside from Friday's close of $33.19. Several firms have raised their targets this month, with Canaccord lifting its price target to $60 from $36 on March 20, citing increased confidence in the drug's premium pricing potential.
What Investors Are Watching
The key focus will be management's commentary on the Phase 3 EMPEROR trial of zorevunersen for Dravet syndrome, a severe genetic epilepsy. The company expects to complete enrollment of 150 patients in the second quarter of 2026, with data readout in mid-2027 to support a rolling new drug application submission in the first half of 2027.
Analysts are particularly interested in updates on FDA engagement. Stoke recently held a multidisciplinary meeting with the agency and has responded to requests for additional information. The central question is whether the drug can secure a broad label addressing the full clinical spectrum of Dravet syndrome -- including cognitive and behavioral improvements -- or whether approval will initially focus on seizure reduction.
Investors will also scrutinize the company's cash position and spending trajectory. With a market capitalization of $1.98 billion and the stock trading near its 52-week high of $40.22, the question is whether current valuation adequately prices in the time and capital needed to reach commercialization.
Recent data published in The New England Journal of Medicine showed zorevunersen's potential for disease modification in Dravet syndrome patients, supporting analyst optimism. Canaccord analyst Sumant Kulkarni noted the firm raised its annual pricing assumption from $300,000 to $600,000, reflecting confidence in the drug's value proposition for a high-unmet-need indication.
The earnings report arrives as Stoke navigates the critical inflection point between clinical development and potential commercialization, with investors weighing near-term losses against the prospect of a breakthrough therapy for a devastating rare disease.